Having confirmed that the loss of LKB1 in our model is responsible for enhanced metabolic activity, we were interested in whether treatment of LKB1−/−NIC mice in vivo with compounds that target the PI3K pathway and mTOR would be effective at inhibiting tumor growth. This evidence concerns the gene STK11 and neoplasm.